EUVIMEDEUVIMED entdecken
Crossref

Inhibition of the Mevalonate Pathway Targets Neuroblastoma Stem Cells

Michelle V Green, Jessie L Reed, Cameron D Zielinski, Jeffrey D Neighbors

Pharmacology · 2025

DOI: 10.1159/000549949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology, 2025. Verfasst von Michelle V Green und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Mevalonic Acid, Neoplastic Stem Cells, Antineoplastic Agents. Die Arbeit nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

High-risk neuroblastoma is a difficult-to-treat cancer with high rates of recurrence and treatment resistance, likely driven by a population of cancer stem cells. Multiple previous studies have suggested that the use of mevalonate pathway inhibitors, such as statins and bisphosphonates, may have anticancer activity against high-risk tumors.

Methods

We aimed to observe the use of mevalonate pathway inhibitors against the cancer stem cell population of high-risk neuroblastoma cell lines SH-SY5Y, SK-N-AS, and SK-N-BE(2)-C using spheroid-based assays.

Results

We observed significant reductions in spheroid formation capability, stem cell frequency, and stemness properties of these neuroblastoma cancer stem cells with fluvastatin and zoledronate treatment.

Conclusion

Treatment with mevalonate pathway inhibitors leads to reduced neuroblastoma cancer stem cell function through reductions in protein geranylgeranylation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaMevalonic AcidNeoplastic Stem CellsAntineoplastic AgentsHumansCell Line, TumorZoledronic AcidFluvastatinSpheroids, CellularHydroxymethylglutaryl-CoA Reductase InhibitorsImidazolesDiphosphonatesIndolesProtein Prenylation

Stichwörter der Autor:innen

BisphosphonateCancer stem cellsMevalonateNeuroblastomaSpheresSpheroidsStatin

Substanzen

Mevalonic AcidZoledronic AcidFluvastatinAntineoplastic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsImidazolesDiphosphonatesIndoles

Autor:innen und Institutionen

  • Department of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA.
  • Penn State Cancer Institute, Hershey, Pennsylvania, USA.
  • Department of Biology, Texas A&M University, College Station, Texas, USA.
  • Department of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA, jneighbors@pennstatehealth.psu.edu.
  • Penn State Cancer Institute, Hershey, Pennsylvania, USA, jneighbors@pennstatehealth.psu.edu.

Zitieren

APA

Green, M. V., Reed, J. L., Zielinski, C. D., & Neighbors, J. D. (2025). Inhibition of the Mevalonate Pathway Targets Neuroblastoma Stem Cells. Pharmacology. https://doi.org/10.1159/000549949

Vancouver

Green MV, Reed JL, Zielinski CD, Neighbors JD. Inhibition of the Mevalonate Pathway Targets Neuroblastoma Stem Cells. Pharmacology. 2025. doi:10.1159/000549949

BibTeX
@article{Green2025,
  author = {Green, Michelle V and Reed, Jessie L and Zielinski, Cameron D and Neighbors, Jeffrey D},
  title = {Inhibition of the Mevalonate Pathway Targets Neuroblastoma Stem Cells},
  journal = {Pharmacology},
  year = {2025},
  doi = {10.1159/000549949}
}
Kostenlos starten →